Effects of systemically administered abaloparatide, an osteoanabolic PTHrP analog, as an adjuvant therapy for spinal fusion in rats.

Arlt H, Besschetnova T, Ominsky MS, Fredericks DC, Lanske B

JOR spine25 Nov 2020Cited by 16 (Europe PMC)

PMID33778406PMCIDPMC7984001DOI10.1002/jsp2.1132PepBankPUB-33778406

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats after spinal fusion surgery, abaloparatide increased serum osteocalcin at day 14 versus vehicle.
In plain wordsIn rats after spinal fusion surgery, abaloparatide increased serum osteocalcin at day 14 versus vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseSerum osteocalcin at day 14
Study
ratn: not reported in source
Sprague-Dawley rats after posterolateral spinal fusion with bone autograft
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/kg/d · subcutaneous · 14 daysAs given in this study (rat).
Source sentences
Summary
Abaloparatide-treated rats showed higher bone formation (serum osteocalcin) at day 14 and 28 compared with vehicle controls, without increases in the bone resorption marker serum TRACP-5b.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of 14 or 28 days of daily subcutaneous injections of abaloparatide (20 μg/kg/d) or vehicle were evaluated in 32 male Sprague-Dawley rats starting 1 day after noninstrumented posterolateral fusion (PLF) with bone autograft.
Report a problemFND-3377840601
02AnimalAnimal study (in vivo)Efficacy outcome
In rats after spinal fusion surgery, abaloparatide increased serum osteocalcin at day 28 versus vehicle.
In plain wordsIn rats after spinal fusion surgery, abaloparatide increased serum osteocalcin at day 28 versus vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseSerum osteocalcin at day 28
Study
ratn: not reported in source
Sprague-Dawley rats after posterolateral spinal fusion with bone autograft
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/kg/d · subcutaneous · 28 daysAs given in this study (rat).
Source sentences
Summary
Abaloparatide-treated rats showed higher bone formation (serum osteocalcin) at day 14 and 28 compared with vehicle controls, without increases in the bone resorption marker serum TRACP-5b.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of 14 or 28 days of daily subcutaneous injections of abaloparatide (20 μg/kg/d) or vehicle were evaluated in 32 male Sprague-Dawley rats starting 1 day after noninstrumented posterolateral fusion (PLF) with bone autograft.
Report a problemFND-3377840602
03AnimalAnimal study (in vivo)Efficacy outcome
In rats after spinal fusion surgery, abaloparatide did not increase serum TRACP-5b versus vehicle.
In plain wordsIn rats after spinal fusion surgery, abaloparatide did not increase serum TRACP-5b versus vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeSerum TRACP-5b
Study
ratn: not reported in source
Sprague-Dawley rats after posterolateral spinal fusion with bone autograft
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/kg/d · subcutaneous · 14 or 28 daysAs given in this study (rat).
Source sentences
Summary
Abaloparatide-treated rats showed higher bone formation (serum osteocalcin) at day 14 and 28 compared with vehicle controls, without increases in the bone resorption marker serum TRACP-5b.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of 14 or 28 days of daily subcutaneous injections of abaloparatide (20 μg/kg/d) or vehicle were evaluated in 32 male Sprague-Dawley rats starting 1 day after noninstrumented posterolateral fusion (PLF) with bone autograft.
Report a problemFND-3377840603
04AnimalAnimal study (in vivo)Efficacy outcome
In rats after spinal fusion surgery, abaloparatide increased fusion mass trabecular number at day 14 versus vehicle.
In plain wordsIn rats after spinal fusion surgery, abaloparatide increased fusion mass trabecular number at day 14 versus vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFusion mass trabecular number
Study
ratn: not reported in source
Sprague-Dawley rats after posterolateral spinal fusion with bone autograft
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/kg/d · subcutaneous · 14 daysAs given in this study (rat).
Source sentences
Summary
Micro-CT showed greater trabecular number in fusion masses from the abaloparatide group vs vehicle controls at day 14.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of 14 or 28 days of daily subcutaneous injections of abaloparatide (20 μg/kg/d) or vehicle were evaluated in 32 male Sprague-Dawley rats starting 1 day after noninstrumented posterolateral fusion (PLF) with bone autograft.
Report a problemFND-3377840604
05AnimalAnimal study (in vivo)Efficacy outcome
In rats after spinal fusion surgery, neither abaloparatide nor vehicle groups showed fusion at day 14.
In plain wordsIn rats after spinal fusion surgery, neither abaloparatide nor vehicle groups showed fusion at day 14.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeFusion at day 14
Study
ratn: not reported in source
Sprague-Dawley rats after posterolateral spinal fusion with bone autograft
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/kg/d · subcutaneous · 14 daysAs given in this study (rat).
Source sentences
Summary
Manual palpation and radiography indicated no fusions in either group at day 14, whereas 25% of vehicle-treated rats and 50% of abaloparatide-treated rats had bilateral fusion at day 28.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of 14 or 28 days of daily subcutaneous injections of abaloparatide (20 μg/kg/d) or vehicle were evaluated in 32 male Sprague-Dawley rats starting 1 day after noninstrumented posterolateral fusion (PLF) with bone autograft.
Report a problemFND-3377840605
06AnimalAnimal study (in vivo)Efficacy outcome
In rats after spinal fusion surgery, bilateral fusion occurred in 50% with abaloparatide versus 25% with vehicle, without statistical significance.
In plain wordsIn rats, bilateral spinal fusion occurred in 50% with abaloparatide versus 25% with vehicle, without statistical significance.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeBilateral fusion at day 28
Study
ratn: not reported in source
Sprague-Dawley rats after posterolateral spinal fusion with bone autograft
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/kg/d · subcutaneous · 28 daysAs given in this study (rat).
Measurements
Bilateral fusion
50%
abaloparatide at day 28
Bilateral fusion
25%
vehicle at day 28
Source sentences
Summary
Manual palpation and radiography indicated no fusions in either group at day 14, whereas 25% of vehicle-treated rats and 50% of abaloparatide-treated rats had bilateral fusion at day 28.
2 context sentences(design, population, supporting numbers)
Summary · context
In summary, this rat PLF model showed that abaloparatide treatment was associated with higher levels of the bone formation marker osteocalcin, improved fusion mass architecture, and a non- significant 2-fold higher fusion rate compared with vehicle.
Summary · context
The effects of 14 or 28 days of daily subcutaneous injections of abaloparatide (20 μg/kg/d) or vehicle were evaluated in 32 male Sprague-Dawley rats starting 1 day after noninstrumented posterolateral fusion (PLF) with bone autograft.
Report a problemFND-3377840606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.